TY  - JOUR
PY  - 2022//
TI  - Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry
JO  - Expert review of neurotherapeutics
A1  - Pillai, Manaswini
A1  - Erridge, Simon
A1  - Bapir, Lara
A1  - Nicholas, Martha
A1  - Dalavaye, Nishaanth
A1  - Holvey, Carl
A1  - Coomber, Ross
A1  - Barros, Daniela
A1  - Bhoskar, Urmila
A1  - Mwimba, Gracia
A1  - Praveen, Kavita
A1  - Symeon, Chris
A1  - Sachdeva-Mohan, Simmi
A1  - Rucker, James J.
A1  - Sodergren, Mikael H.
SP  - ePub
EP  - ePub
VL  - ePub
IS  - ePub
N2  - BACKGROUND: The current paucity of clinical evidence limits the use of cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality of life (HRQoL) changes and adverse events in patients prescribed CBMPs for PTSD. <br><br>METHODS: A case-series of patients from the UK Medical Cannabis Registry was analyzed. HRQoL was assessed at 1-, 3-, and 6-months using validated patient reported outcome measures (PROMs). Adverse events were analyzed according to the Common Terminology Criteria for Adverse Events version 4.0. Statistical significance was defined as p < 0.050. <br><br>RESULTS: Of 162 included patients, 88.89% (n = 144) were current/previous cannabis users. Median daily CBMP dosages were 5.00 (IQR: 0.00-70.00) mg of cannabidiol and 145.00 (IQR: 100.00-200.00) mg of Δ9-tetrahydrocannabinol. Significant improvements were observed in PTSD symptoms, sleep, and anxiety across all follow-up periods (p < 0.050). There were 220 (135.8%) adverse events reported by 33 patients (20.37%), with the majority graded mild or moderate in severity (n = 190, 117.28%). Insomnia and fatigue had the greatest incidence (n = 20, 12.35%). <br><br>CONCLUSIONS: Associated improvements in HRQoL were observed in patients who initiated CBMP therapy. Adverse events analysis suggests acceptability and safety up to 6 months. This study may inform randomized placebo-controlled trials, required to confirm causality and determine optimal dosing.<p />  <p>Language: en</p>
LA  - en
SN  - 1473-7175
UR  - http://dx.doi.org/10.1080/14737175.2022.2155139
ID  - ref1
ER  -